BCMA-targeted immunotherapy for multiple myeloma

• Published in: Journal of hematology and oncology 2020-09, Vol.13 (1), p.125-24, Article 125
• Main Authors: Yu, Bo, Jiang, Tianbo, Liu, Delong
• Format: Article
• Language: English
• Subjects: Antibodies; Antibodies, Bispecific - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Antibody-drug conjugate; Antigens; Antineoplastic Agents - therapeutic use; B cell maturation antigen; B cells; B-Cell Maturation Antigen - antagonists & inhibitors; B-Cell Maturation Antigen - genetics; B-Cell Maturation Antigen - immunology; B-Cell Maturation Antigen - physiology; B-Lymphocytes - immunology; B-Lymphocytes - metabolism; B-Lymphocytes - pathology; BCMA; Belantamab mafodotin; Biological products; Biomarkers; Bispecific T cell engager; CAR-T; Cell adhesion & migration; Cell cycle; Chimeric antigen receptors; Clinical Trials as Topic; Cytotoxicity; Developmental stages; Hematology; Heparan sulfate; Humans; Immunoconjugates - therapeutic use; Immunotherapy; Immunotherapy, Adoptive; Kinases; Ligands; Lymphocytes T; Medical prognosis; Molecular Targeted Therapy; Monoclonal antibodies; Multicenter Studies as Topic; Multiple myeloma; Multiple Myeloma - immunology; Multiple Myeloma - therapy; Neoplasm Proteins - antagonists & inhibitors; Neoplasm Proteins - genetics; Neoplasm Proteins - immunology; Neoplasm Proteins - physiology; Oncology; Plasma cells; Plasma Cells - drug effects; Plasma Cells - metabolism; Protein Isoforms - antagonists & inhibitors; Protein Isoforms - immunology; Randomized Controlled Trials as Topic; Review; T cells; Targeted cancer therapy; Transcription factors; Tumor necrosis factor-TNF; Viral antibodies
• ISSN: 1756-8722; 1756-8722
• DOI: 10.1186/s13045-020-00962-7

B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.